KK Lim

A curious health economist | 💭🔎🖊 #HealthServices #HealthPolicy #PopHealth #SystemThinking #rstats | MPharm,MSc,PhD | Own views | Follow / RT / Like ≠ Endorse

[KK Lim @kakeatlim]

@TradfiBaby @robj3d3 Buses in London charge per ride, so no tapping off.
Buses in SG charge based on distance travelled, so tapping off is needed. The bus fare is integrated with their tube (MRT) - if I board a bus right after MRT, my bus fare is highly discounted. In London, bus & tube r separate

[KK Lim @kakeatlim]

Health System Impact Fellowship in Canada, by Canadian Institutes of Health Research.
https://t.co/vjpqG6Iv6i
- PhD students - 1 year @ CAD$45k + training allowance CAD$5k
- Postdoc - 2 years @ CAD 70k per year + training allowance CAD$7.5k per year

[KK Lim @kakeatlim]

So, if you see any that named me as a speaker, this is without my consent / knowledge. I would advise against registering for it. I would also advise my fellow colleagues, especially those in academia, to be vigilant on potential misuse of their names.

[KK Lim @kakeatlim]

A kind colleague has alerted me that I have been "named" as a speaker in an upcoming public health conference scheduled to be held in February 2026. I would like to clarify that I have not agreed to speak at any conference in 2026.

[KK Lim @kakeatlim]

<50% EEs reported intervals,diagnostic method, treatment & screening locations. None reported all aspects of screening designs.

We recommend future EEs of T2DM screening to report all aspects of screening designs, to allow synthesis and assessment of findings transferability.

[KK Lim @kakeatlim]

In our latest work, we reviewed recent economic evaluations (EEs) of screening for type 2 diabetes mellitus (T2DM) according to the comparators and screening designs.

https://t.co/0f4RdSbX74

We highlight our findings in the comments below.

[KK Lim @kakeatlim]

Limitations:

(1) These observations are generalisations of multiple screening designs e.g., screening programme of different screening intervals, screening locations, etc.

(2) Some comparisons were contributed by single EEs.

[KK Lim @kakeatlim]

[Seeking ideas] Say we develop an early model for a new tech & would like to estimate EVPPI for the efficacy parameter. The tech hasn't been tested clinically, so efficacy is hypothetical. How to interpret EVPPI for efficacy data in such a case? Or should EVPPI not be done? TQ!

[Consilium Scientific @consiliumsci]

Join Consilium for the first discussion panel of 2025 on Thursday, 30th January with @CRUKresearch!

❓The Challenges of Screening for Cancer: The Use of Surrogate Endpoints

🕔Thursday 30th January, 5pm London Time

Find out more here: https://t.co/nXpVtdFGzV

[KK Lim @kakeatlim]

Join us in this online panel on transitioning across sectors for early-career health economists, scheduled 9 Feb (Mon) 9am GMT. Featuring 3 panelists who have crossed from academia to gov, non-profit, consultancy and pharma.
https://t.co/G56HOKKUX1

https://t.co/lcTgV30ChY

[International Health Economics Association (IHEA) @healtheconomics]

Join us on Feb 3rd for an exciting panel discussion with three health economists "shifters", who will share their personal journeys of transitioning across sectors. Learn more and add to your calendar here: https://t.co/pc08WSHq87

[KK Lim @kakeatlim]

@markcheongwl I think, if the MOH does plan for public hospitals to provide private service and charging private fees (under Rakan MOH), putting MOH facilities up through the same regulation will be inevitable.

[Wolfson Institute of Population Health @QMUL_WIPH]

To find out more about the Masters in Global Public Health (Distance Learning) programme - Join our online event on Thursday 20 November:

https://t.co/PV9XJz3yu1

[KK Lim @kakeatlim]

@alene_yong @MonashUni @markcheongwl Congrats, Alene! Very well done!

[JAHA @JAHA_AHA]

What is the economic evidence for genetic-guided pharmacotherapy for CAD, and what variables affect its cost-effectiveness?

Read this systematic review to find out. #AHAJournals @kakeatlim @RositsaKolarova @lifecourse_KCL @kingsmedicine @HERC_Oxford https://t.co/pGzLE9eyse

[Iain Marshall @ijmarshall]

We have a great opportunity for a funded PhD studentship, looking at using Large Language Models for evidence synthesis, and clinical information. Apply via the DRIVE health scheme (project 77) https://t.co/R32mPqW1Xt

[KK Lim @kakeatlim]

TQ @kingsmedicine & @lifecourse_KCL for the feature! 🙏
Very happy to be contributing to ECRTs in @lifecourse_KCL through our Early Career Research and Teaching Network and HEOR through @ISPORorg.

[King's Faculty of Life Sciences & Medicine @kingsmedicine]

We recently spoke to @kakeatlim, Research Fellow in Health Economics @lifecourse_KCL, about his career and the importance of building connections and engaging with the scientific and research community

Read more ⬇️

https://t.co/qNTxGyOXfR

[KK Lim @kakeatlim]

Thank you to @RositsaKolarova, @haninfarhana and all co-authors for your contributions!! 🙏

[KK Lim @kakeatlim]

Very glad to see this paper out!
Even with the same gene, there r many ways to do the test, how test results r used to inform prescription, & the usual care compared against testing. These affect findings, hence important for studies to spell out clearly in their methods section!

[Economics of Population Health Research Centre @EPH_Oxford]

NEW PUBLICATION

Genetic‐Guided Pharmacotherapy for Coronary Artery Disease: A Systematic and Critical Review of Economic Evaluations

@kakeatlim @RositsaKolarova @Kings_PHS @JAHA_AHA

https://t.co/olDyS2Aiyk